Welcome to our dedicated page for Zomedica news (Ticker: ZOMDF), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp. (ZOMDF) is an animal health company focused on diagnostic, therapeutic, and monitoring devices for equine and companion animals. This news page aggregates company announcements, product updates, financial disclosures, and strategic communications so readers can follow how Zomedica is executing its stated growth plans in veterinary devices and services.
Recent news highlights Zomedica’s work across multiple platforms. The company has reported launches and expansions within its TRUFORMA in-clinic diagnostic platform, including an equine progesterone assay for reproductive management and feline validation for its multiplexed cobalamin and folate assay. It has also announced enhancements to its VETGuardian Zero Touch monitoring platform through the VETGuardian PLUS monitor, which adds a built-in display, remote viewing, and imaging features to support workflow efficiency in clinics.
On the therapeutic side, Zomedica has issued press releases about the Assisi Loop Lounge tPEMF therapy bed, positioned as an evidence-based, non-pharmaceutical option for pain and inflammation, and has continued to emphasize the role of its PulseVet shock wave system in musculoskeletal healing. News items also cover distribution agreements, such as an expanded partnership with Grovet b.v. in Europe, and collaborations that raise awareness of its Assisi and Calmer Canine technologies.
Investors can also find coverage of Zomedica’s quarterly financial results, including segment performance across diagnostics, therapeutic devices, and development services, as well as liquidity and margin commentary. Regular “Fourth Friday at Four” webinars and related special sessions are announced through press releases, providing additional context on strategy, product platforms, and business performance. Bookmark this page to review Zomedica’s ongoing disclosures and corporate developments over time.
Zomedica (OTCQB: ZOMDF) announced a strategic collaboration with Boehringer Ingelheim Animal Health Canada to expand use of its TRUFORMA platform for equine endocrine testing, focusing on pituitary pars intermedia dysfunction (PPID) across Canada starting with the upcoming fall testing season.
Under the agreement, Zomedica will support placement of TRUFORMA analyzers in participating equine veterinary practices, while Boehringer Ingelheim will offer eligible customers complimentary PPID diagnostic testing using Zomedica’s eACTH and equine insulin assays. TRUFORMA analyzers and diagnostic cartridge kits will be provided at no cost to participating practices and eligible Boehringer Ingelheim customers, which is expected to expand Zomedica’s installed base and expose veterinarians to additional equine assays such as Cortisol and Progesterone.
Zomedica reports 2025 revenue of $32 million, up 17%, and revenue of $18 million for the six months ended June 30, 2026, up 36%, with approximately $44 million in liquidity at June 30, 2026.
Zomedica (OTCQB:ZOMDF) announced the next "Fourth Friday at Four" investor webinar, titled "Zomedica International: Building a Global Platform for Veterinary Innovation," to be held on Friday, August 28, 2026, at 4:00 p.m. Eastern Time. The session will focus on the company’s international expansion strategy, distributor infrastructure, global market opportunity, and commercial leadership across Europe, Asia-Pacific, the Middle East, and the Americas.
The webinar will highlight how Zomedica is building an asset-light, partnership-driven global distribution network and applying its multi-product platform and recurring revenue model outside North America. Zomedica reports 2025 revenue of $32 million (up 17%), revenue of $18 million for the six months ended June 30, 2026 (up 36%), and approximately $44 million in liquidity as of June 30, 2026. Its portfolio, including PulseVet, Assisi Loop, TRUFORMA, TRUVIEW, VETGuardian PLUS and VETIGEL, addresses a U.S. market exceeding $2 billion, supported by about 150 employees and manufacturing in Georgia and Minnesota.
Zomedica (OTCQB: ZOMDF) reported record Q2 2026 revenue of $9.5 million, up 37% from $7.0 million in Q2 2025, marking its 22nd consecutive quarter of year-over-year growth. Six-month 2026 revenue rose 36% to $18.3 million.
Q2 growth was driven by a 77% increase in Diagnostics revenue to $1.4 million, 9% growth in Therapeutic Devices to $6.8 million, and ongoing contributions from the Development Services segment, which generated $1.4 million in Q2 and $3.4 million year-to-date. Consumables revenue grew 26% to $6.6 million and Capital sales increased 11% to $1.9 million. Gross margin reached 64% in Q2 and 63% year-to-date.
Total Q2 operating expenses declined 20% to $10.1 million, with research and development down 43%, selling and marketing down 21%, and general and administrative down 13%. Net loss narrowed to $3.8 million from $7.4 million a year earlier, while Q2 Non-GAAP EBITDA loss improved to $2.2 million from $5.8 million. Cash burn fell 38% to $3.4 million, the lowest non-year-end quarterly level on record. As of June 30, 2026, Zomedica reported $44.1 million in cash, cash equivalents, and available-for-sale securities and 979,949,668 common shares outstanding.
Zomedica (OTCQB: ZOMDF) announced the launch of the PulseVet Acoustic Muffler(TM), an accessory for PulseVet(R) shock wave therapy systems designed to significantly reduce treatment noise while maintaining energy delivery and clinical efficacy. The muffler redirects and dampens unnecessary noise without altering the therapeutic beam, aiming to create a quieter environment for veterinarians, patients, and caregivers.
The accessory integrates simply with existing PulseVet systems and is intended for musculoskeletal and orthopedic applications. According to Zomedica, the U.S. total addressable market for its product suite exceeds $2 billion, 2025 revenue grew 17% to $32 million, and liquidity was about $48 million as of March 31, 2026.
Zomedica (OTCQB: ZOMDF) announced the next session of its recurring investor webinar series, "Fourth Friday at Four," to be held on Friday, July 24, 2026 at 4:00 p.m. Eastern Time. The July program, titled "Zomedica's Sales Organization: From Strategy to the Clinic," will focus on how the company’s specialized commercial organization supports discovery, adoption, and integration of its point-of-care diagnostic and therapeutic products in veterinary practices.
The webinar will feature Zomedica’s U.S. sales footprint, territory coverage, and role structure, including Account Managers, Capital Equipment Specialists, Inside Sales Representatives, and Professional Services Veterinarians. Led by CEO Larry Heaton and Senior Vice President of Sales Kevin Klass, the session will connect the sales organization to Zomedica’s Five Pillars framework, customer adoption, clinical utilization, and long-term commercial growth. The format includes customer testimonials, prepared remarks, a feature on the sales organization, and a live Q&A. Registration is available online.
Zomedica (OTCQB:ZOMDF) renewed its alliance with Fear Free, designating Assisi Loop tPEMF therapy products as compatible with Fear Free’s low-stress care approach.
The collaboration aims to educate veterinary teams, expand awareness of non-invasive, drug-free tPEMF options for pain and inflammation, and support calmer care experiences for pets and owners.
Zomedica (OTCQB:ZOMDF) will host its next “Fourth Friday at Four” investor webinar on June 26, 2026 at 4:00 p.m. ET. The session will explain Zomedica’s Five Pillars framework and link clinical value, veterinary practice performance, and recurring revenue growth across its product portfolio.
Zomedica (OTCQB:ZOMDF) renewed its sponsorship with the United States Eventing Association, keeping PulseVet as the “Official Shock Wave of the USEA.”
The partnership supports equine health and performance through educational outreach, event presence, and wellness and rehabilitation initiatives focused on Eventing horses and their care teams.
Zomedica (OTCQB:ZOMDF) will host its next “Fifth Friday at Four” investor webinar on May 29, 2026 at 4:00 p.m. ET. The session will review Q1 2026 financial results and provide a deep dive into the companion animal VetTech market, including products, workflows, and long-term growth opportunities.
Zomedica (OTCQB: ZOMDF) reported Q1 2026 revenue of $8.8 million, up 35% year-over-year, marking its 21st consecutive quarter of YoY revenue growth. Gross margin was 62%, cash and equivalents totaled $47.5 million, and Q1 net loss was $4.5 million.
Diagnostics grew 73% year-over-year to $1.0 million, Development Services generated $2.0 million in Q1, and operating expenses excluding last year’s impairment fell 21% versus Q1 2025.